



Noxopharm Pipeline Boosted by \$1.5M Grant to Hudson Institute of Medical Research

Highlights

- Noxopharm strategic partner Hudson Institute of Medical Research receives \$1.5 million National Health and Medical Research Council grant
- Funding supports Noxopharm's Sofra™ pipeline to further develop first-in-class drug candidates
- Scientific community backs novel therapeutic approach to treatment of chronic inflammatory conditions

Sydney 16 December 2022: Innovative Australian biotech **Noxopharm Limited (ASX:NOX)** is pleased to announce that one of its key strategic partners, Melbourne's **Hudson Institute of Medical Research**, has received a \$1,496,654 grant from Australia's National Health and Medical Research Council.

The NHMRC Ideas Grant scheme is highly competitive. Traditionally only around 10% of applications receive funding, and in 2021 the mean amount awarded was approximately [\\$965,000](#).

The four-year grant will support innovative research into novel treatments for autoimmune diseases. These affect over one million Australians, plus many more around the world, and treatment options remain limited.

A team of Australian researchers led by [Associate Professor Michael Gantier](#) of the [Hudson Institute](#), including Dr Julia Ellyard and Professor Ben Corry from Australian National University (ANU), is developing a new class of RNA therapeutics. These selectively inhibit a protein known as TLR7, which is overactivated in diseases like lupus.

The ongoing work at the Hudson Institute and ANU is a collaborative effort with Noxopharm subsidiary Pharmorage under the company's Sofra™ technology platform. The research involves defined goals, as well as robust and secured intellectual property with considerable commercial potential.

This grant is in addition to two recent grants that were received to support Noxopharm and Hudson Institute's collaborative efforts in discovering new anti-inflammatory treatments:

- The [\\$1.45 million funding](#) Hudson Institute received earlier this year from the Victorian Government, for research aiming to identify novel drug compounds that dampen harmful excessive inflammation associated with COVID-19.

- The matched [\\$100,000 Victorian mRNA Acceleration Fund](#) grant obtained to develop RNA-based therapeutics to manage TLR7-driven autoimmune diseases.

Noxopharm CEO Dr Gisela Mautner said: “We have a very productive relationship with the Hudson Institute team and are delighted to see them receive this grant. It will support innovation in an area of medical research that is attracting more interest than ever before, and the drugs we are looking to develop in this space would be something genuinely new in this sector. This research is key to our proprietary Sofra™ technology platform, which is a fundamental component of the preclinical pipeline we are building as part of our multi-platform strategy.”

Hudson Institute A/Prof Michael Gantier said: “We are delighted to see recognition of our pioneering work on TLR7 rewarded by this NHMRC funding. In addition to supporting the development of an entirely new class of TLR7 inhibitors, this work will help broaden our basic understanding of the role of TLR7 in the progression of autoimmunity. If our hypothesis is correct, therapies targeting TLR7 could be designed to halt progression of a wide range of diseases otherwise fuelled by auto-antibodies.”

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation.

It has three active drug development programs: its clinical drug candidate Veyonda®, plus two innovative technology platforms – Chroma™ (oncology) and Sofra™ (inflammation and autoimmunity), which provide the basis for active development of a growing pipeline of new proprietary drugs.

Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: www.noxopharm.com

About Hudson Institute of Medical Research

A global bioscience medical research leader, Hudson Institute’s sole focus is on powering breakthrough scientific discoveries into improved health care that will transform lives. We strive to improve human health through ground-breaking, collaborative, medical research discoveries and the translation of these to real world impact.

Hudson Institute scientists research five areas of medical need

- Inflammation
- Reproductive health and pregnancy



- Infant and child health
- Cancer
- Hormones and health

To learn more, please visit: www.hudson.org.au

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Hudson Institute Media enquiries:

Rob Clancy

Communications & Media Manager

M: + 61 408 579 313

E: rob.clancy@hudson.org.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.